Context Therapeutics Inc. - Common Stock (CNTX)
CUSIP: 21077P108
Q1 2024 13F Holders as of 31 Mar 2024
- Type / Class
- Equity / Common Stock
- Shares outstanding
- 91,741,639
- Total 13F shares
- 3,935,132
- Share change
- +376,493
- Total reported value
- $5,430,813
- Price per share
- $1.38
- Number of holders
- 25
- Value change
- +$524,452
- Number of buys
- 10
- Number of sells
- 5
Quarterly Holders Quick Answers
What is CUSIP 21077P108?
CUSIP 21077P108 identifies CNTX - Context Therapeutics Inc. - Common Stock in SEC institutional holdings data.
Need full ownership history?
Open the full security ownership history page.
Next holder-history checks
These links keep the next click tied to holder verification, nearby quarters, or outside-13F ownership context.
- Back to full security ownership history for the broader multi-quarter picture.
- Latest 13F filings for newly reported positions across managers.
- Latest Schedule 13D/13G reports for ownership changes outside the 13F cadence.
- SEC investors directory for manager drilldown.
Explore More Reporting Periods
Jump to adjacent filing periods for faster comparison and easier crawl discovery.
Recent filing periods for CUSIP 21077P108:
Top shareholders of CNTX - Context Therapeutics Inc. - Common Stock (13F + 13D/G + 3/4/5)
Grouped by holder across the latest SEC ownership disclosures. Ownership % is shown only when it is directly reported or safely comparable across share classes.
Methodology: rows are grouped by holder and ranked by the holder's primary source value. — indicates unavailable or non-comparable values; "mixed-class rows" means the latest filing spans non-comparable classes.
| Holder | Source | Role / Reporting | Ownership % | Shares | Holdings Value | 12M Net Δ | As of | Details |
|---|---|---|---|---|---|---|---|---|
| Opaleye Management Inc. |
13F
|
Company |
1.1%
|
975,000
|
$1,101,750 | — | 31 Dec 2023 | |
| Ally Bridge Group (NY) LLC |
13F
|
Company |
0.79%
|
725,951
|
$820,325 | — | 31 Dec 2023 | |
| VANGUARD GROUP INC |
13F
|
Company |
0.65%
|
596,012
|
$673,494 | — | 31 Dec 2023 | |
| Affinity Asset Advisors, LLC |
13F
|
Company |
0.36%
|
328,817
|
$371,563 | — | 31 Dec 2023 | |
| OCONNOR, A Distinct Business Unit of UBS ASSET MANAGEMENT AMERICAS (LLC) |
13F
|
Company |
0.32%
|
296,675
|
$335,243 | — | 31 Dec 2023 | |
| HighTower Advisors, LLC |
13F
|
Company |
0.14%
|
125,852
|
$142,000 | — | 31 Dec 2023 | |
| BRIDGEWAY CAPITAL MANAGEMENT, LLC |
13F
|
Company |
0.12%
|
105,809
|
$119,564 | — | 31 Dec 2023 | |
| Mill Creek Capital Advisors, LLC |
13F
|
Company |
0.11%
|
104,631
|
$118,233 | — | 31 Dec 2023 | |
| GEODE CAPITAL MANAGEMENT, LLC |
13F
|
Company |
0.11%
|
97,240
|
$109,932 | — | 31 Dec 2023 | |
| NORTHERN TRUST CORP |
13F
|
Company |
0.04%
|
37,219
|
$42,057 | — | 31 Dec 2023 | |
| Clear Harbor Asset Management, LLC |
13F
|
Company |
0.04%
|
36,000
|
$40,680 | — | 31 Dec 2023 | |
| STATE STREET CORP |
13F
|
Company |
0.04%
|
32,907
|
$37,185 | — | 31 Dec 2023 | |
| RENAISSANCE TECHNOLOGIES LLC |
13F
|
Company |
0.04%
|
32,200
|
$36,000 | — | 31 Dec 2023 | |
| SHEETS SMITH WEALTH MANAGEMENT |
13F
|
Company |
0.02%
|
20,000
|
$22,600 | — | 31 Dec 2023 | |
| CITADEL ADVISORS LLC |
13F
|
Company |
0.02%
|
15,880
|
$17,944 | — | 31 Dec 2023 | |
| Aspire Wealth Management Corp |
13F
|
Company |
0.01%
|
10,000
|
$11,300 | — | 31 Dec 2023 | |
| UBS Group AG |
13F
|
Company |
0.01%
|
9,490
|
$10,724 | — | 31 Dec 2023 | |
| Tarek Sahmoud |
3/4/5
|
Chief Medical Officer |
—
mixed-class rows
|
35,000
mixed-class rows
|
$8,415 | — | 16 Aug 2022 | |
| Tower Research Capital LLC (TRC) |
13F
|
Company |
0.01%
|
6,655
|
$7,520 | — | 31 Dec 2023 | |
| OSAIC HOLDINGS, INC. |
13F
|
Company |
0%
|
1,500
|
$1,695 | — | 31 Dec 2023 | |
| Federation Des Caisses Desjardins du Quebec |
13F
|
Individual |
0%
|
400
|
$452 | — | 31 Dec 2023 | |
| Retirement Group, LLC |
13F
|
Company |
0%
|
155
|
$175 | — | 31 Dec 2023 | |
| WELLS FARGO & COMPANY/MN |
13F
|
Company |
0%
|
114
|
$129 | — | 31 Dec 2023 | |
| BANK OF AMERICA CORP /DE/ |
13F
|
Company |
0%
|
109
|
$123 | — | 31 Dec 2023 | |
| JPMORGAN CHASE & CO |
13F
|
Company |
0%
|
23
|
$26 | — | 31 Dec 2023 | |
| Evan G. Dick |
3/4/5
|
Former Section 16 officer |
—
class O/S missing
|
29,223
|
— | — | 15 Feb 2022 | |
| William F. Rencher |
3/4/5
|
Former Section 16 officer |
—
class O/S missing
|
8,000
|
— | — | 15 Feb 2022 |
Institutional Holders of Context Therapeutics Inc. - Common Stock (CNTX) as of Q1 2024
As of 31 Mar 2024,
Context Therapeutics Inc. - Common Stock (CNTX) was held by
25 institutional
shareholders
that filed Form 13F with the SEC.
Together, they reported ownership of
3,935,132 shares.
The largest 10 holders included
Opaleye Management Inc., Ally Bridge Group (NY) LLC, VANGUARD GROUP INC, Affinity Asset Advisors, LLC, OCONNOR, A Distinct Business Unit of UBS ASSET MANAGEMENT AMERICAS (LLC), ADAR1 Capital Management, LLC, HighTower Advisors, LLC, BRIDGEWAY CAPITAL MANAGEMENT, LLC, Mill Creek Capital Advisors, LLC, and GEODE CAPITAL MANAGEMENT, LLC.
This page lists
25
institutional shareholders reporting positions in this security
for the Q1 2024 filing period.
| Investor | Option | Weight % | Change % | Value $ | * Price | Shares | Share Change | Activity | Report Period |
|---|
Compare Q1 2024 vs Q4 2023 Across Filers
Q4 2023 holders
24
Q1 2024 holders
25
Holder diff
1
| Investor | Q4 2023 Shares | Q1 2024 Shares | Share Diff | Share Chg % | Q4 2023 Value $ | Q1 2024 Value $ | Value Diff $ | Value Chg % |
|---|
Trend: ostatnie 8 kwartałów (+ wybrane okresy porównania).
Quarterly Holders Trend
Quarterly Value Trend
Quarterly Shares Trend
* Reported Price is the price of the security as of the portfolio date. This value is significant in that it is the last known price at which the security was still held.
An asterisk sign (*) next to the price indicates that the price is likely invalid.
An asterisk sign (*) next to the price indicates that the price is likely invalid.